Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38

@inproceedings{Escande2013FlavonoidAI,
  title={Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38},
  author={Carlos J Escande and Veronica Nin and Nathan L. Price and Verena Capellini and Ana Patr{\'i}cia Gomes and Maria Thereza P Barbosa and Luke O’Neil and Thomas A. White and David A Sinclair and Eduardo Nunes Chini},
  booktitle={Diabetes},
  year={2013}
}
Metabolic syndrome is a growing health problem worldwide. It is therefore imperative to develop new strategies to treat this pathology. In the past years, the manipulation of NAD(+) metabolism has emerged as a plausible strategy to ameliorate metabolic syndrome. In particular, an increase in cellular NAD(+) levels has beneficial effects, likely because of the activation of sirtuins. Previously, we reported that CD38 is the primary NAD(+)ase in mammals. Moreover, CD38 knockout mice have higher… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…